Martin Schneider

Martin Schneider

Company: Novartis

Job title: Associate Director


Modulating T cell Metabolism – From a Type I Kinase Inhibitor to an Oral Heterobifunctional Kinase Degrader 3:30 pm

Starting from an efficacious in vitro / in vivo active type I kinase inhibitor Degrading the kinase instead of blocking it has the same in vitro cellular effects on primary T cell metabolism Optimizing a kinase inhibitor into an oral bifunctional degrader for in vivo useRead more

day: Day Two

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.